Lynparza Archives - Pharmaphorum

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

https://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/

AZ/MSD’s Lynparza sees positive results in prostate cancer

https://pharmaphorum.com/news/az-msds-lynparza-sees-positive-results-in-prostate-cancer/

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancer

https://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/

Lynparza on cusp of approval for advanced ovarian cancer

https://pharmaphorum.com/news/lynparza-on-cusp-of-approval-for-advanced-ovarian-cancer/

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer

https://pharmaphorum.com/news/az-and-msds-lynparza-gets-eu-nod-for-hard-to-treat-breast-cancer/

AstraZeneca cancer drugs approved in Japan

https://pharmaphorum.com/r-d/astrazenecas-cancer-drugs-approved-japan/

Tesaro and Roche to combine drugs in bladder cancer trials

https://pharmaphorum.com/news/tesaro-roche-combine-drugs-bladder-cancer-trials/

Lynparza first PARP drug to show promise in breast cancer

https://pharmaphorum.com/news/lynparza-first-parp-drug-show-promise-breast-cancer/

Cancer market commentary: 3 highlights from ESMO (Part 1)

https://pharmaphorum.com/esmo-2016/cancer-market-commentary-3-highlights-esmo-conference-part-1/

Search